Company Profile

Seismic Therapeutic

Profile date: 2026-06-15

Comprehensive Corporate Writeup: Seismic Therapeutic, Inc.

Executive Summary

Seismic Therapeutic, Inc. is a clinical-stage biotechnology company that pioneers the integration of machine learning across the entire biologics discovery and development process. Self-described as "The Machine Learning Immunology Company," the entity focuses on treating dysregulated adaptive immunity to address a broad range of chronic and acute autoimmune, inflammatory, and allergic diseases. By treating drug development as a parallelized rather than linear process, Seismic seeks to discover first-in-class and best-in-class therapeutic antibodies and enzymes with optimized drug-like attributes and minimized immunogenicity.

Company Overview & Location

Founded in 2020 by a team of veteran biotechnology entrepreneurs, immunologists, and computer scientists, Seismic Therapeutic represents a structural shift in immunology drug discovery.

Headquarters: 250 Arsenal Place, Suite 210, Watertown, MA 02472, United States (located within the Boston biotechnology hub).
Key Leadership: Led by Founder, President, and CEO Jo Viney, PhD (formerly co-founder of Pandion Therapeutics), alongside Chief Research Officer Kevin Otipoby, PhD, and Chief Medical Officer & Head of R&D John Sundy, MD, PhD.
Academic & Strategic Roots: Co-founded by prominent industry and academic figures, including Timothy A. Springer, PhD (Harvard Medical School).
Financing: The company is backed by prominent life science venture investors (including Polaris Partners, Lightspeed Venture Partners, and Bessemer Venture Partners), securing major financing milestones such as a $101 million Series A in 2022 and a $146 million Series B in late 2023.

Core Technology: The IMPACT™ Platform

The backbone of Seismic Therapeutic’s methodology is its proprietary IMPACT (Integrative Machine Learning Protein Advanced Choice Technology) platform. Traditional biologics discovery relies on sequential trial-and-error iterations to optimize a molecule for efficacy, stability, and manufacturability, which frequently results in development bottlenecks.

The IMPACT platform circumvents this by fully parallelizing the discovery phase. It systematically integrates four distinct scientific domains: 1. Machine Learning: Deployed to explore vast novel sequence spaces, map protein-protein interfaces, and predict higher-order residue dependencies (epistasis). 2. Structural Biology: Used to understand molecular geometry and design highly target-specific interfaces. 3. Protein Engineering: Applied to physically build, alter, and refine enzyme and antibody structures. 4. Translational Immunology: Utilized to map disease mechanisms directly to human clinical profiles.

Key Capabilities of the IMPACT Platform

Multi-Property Optimization: Simultaneously designs for therapeutic potencies, binding kinetics, expression yields, and scalability rather than optimizing one trait at a time.
Invisibilization (De-immunization): Utilizing predictive machine learning models, the platform identifies and structurally removes potentially immunogenic T cell and B cell epitopes from therapeutic proteins. This masks the drug from the patient's immune system, minimizing anti-drug antibodies (ADAs) and extending the therapeutic half-life.
In Silico Epitope Binning: Predicts the exact binding regions (epitopes) recognized by proprietary antibodies to establish direct epitope-to-function relationships early in development.

Products, Services, and Therapeutic Pipeline

Seismic Therapeutic is a product-centric entity. It does not operate as a contract service provider; rather, it utilizes its platform to build a proprietary asset pipeline. The company's therapeutic offerings target the two central pillars of the adaptive immune system: cell-mediated immunity (T cell-driven) and humoral immunity (antibody/B cell-driven).

The product pipeline is organized into three primary therapeutic areas:

1. Cell-Mediated Immune Diseases (Dual-Cell Checkpoint Agonism)

For diseases caused by inappropriately activated T cells, Seismic develops multi-functional antibody therapies engineered to restore immune homeostasis by activating multiple inhibitory pathways across the immune cell synapse.

S-4321 (PD-1:FcγRIIb Agonist Antibody): This is Seismic's most advanced clinical-stage program. It is a non-depleting, bifunctional antibody designed to down-regulate overactive immune responses. It operates via a dual mechanism:
- It agonizes PD-1, a well-characterized inhibitory checkpoint receptor found on T effector cells.
- It selectively engages and agonizes the inhibitory Fc gamma receptor IIb (FcγRIIb) located on B cells and antigen-presenting cells.
- Platform Differentiation: The platform was used to engineer a highly specialized Fc domain that precisely tunes binding properties at the Fc/FcγRIIb interface, maximizing checkpoint agonism without causing target cell depletion.

2. Antibody-Mediated Immune Diseases (Immunoglobulin Sculpting Enzymes)

For diseases driven by pathogenic autoantibodies attacking host tissues or transplants, Seismic designs "Immunoglobulin Sculpting" (IgSc) enzyme therapeutics. These enzymes are engineered to degrade problematic immunoglobulins while preserving general immune equilibrium.

Pan-IgG Proteases: Novel, selective enzymes designed to rapidly cleave and eliminate circulating Immunoglobulin G (IgG) and IgG-driven immune complexes. By cleaving these target antibodies, the enzymes eliminate downstream effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), while cutting off the signal that activates memory B cells.
IgM Proteases: Enzymes customized to target and selectively cleave Immunoglobulin M (IgM) components involved in acute antibody-mediated pathologies.
Platform Differentiation: Naturally occurring enzymes that degrade antibodies are often recognized as foreign by the human body. Seismic applies its machine learning workflow to remove immunogenic patches from these bacterial enzymes, making them suitable for repeated clinical dosing.

3. Allergic Diseases (IgE-Targeted Programs)

For Type I hypersensitivity and chronic allergic conditions governed by Immunoglobulin E (IgE) and subsequent mast cell/basophil degranulation, Seismic is developing multiple therapeutic biologics intended to stop allergic inflammation at its source.

IgE-Specific Proteases: Designed to cleave and eliminate free, circulating IgE before it can bind to high-affinity receptors on immune effector cells.
Fc-Fused IgE Dissociators: Specialized biologics engineered to actively detach bound IgE from effector cells and down-modulate their activation.
IgE Sweepers: Monoclonal mechanisms engineered to capture and rapidly clear free IgE from tissue microenvironments and systemic circulation.

Summary of Pipeline Programs

Please note: This information is generated by AI. For legal use, verify with company sources.